About
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Current Value
$25.201 Year Return
Current Value
$25.201 Year Return
Key Details
Market Cap
$9.93B
P/E Ratio
-2.77
1Y Stock Return
-74.84%
1Y Revenue Growth
-52.75%
Dividend Yield
0.00%
Price to Book
0.9
Strategies that include MRNA
Double maintains 8 strategies that include MRNA - Moderna, Inc.
US Top 500
Medium risk
$14.0K
The textbook passive investment vehicle is generally considered to comprise of 500 of the largest stocks traded within the US. Double's take on this exposes a client to the US stock market in a diversified way without any expense ratio.
Top Sector
Information Technology
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
502
Growth at a Fair Price
High risk
$1,000
These stocks above $1B in Market Cap are modestly valued (PE below 15) but are in the top 20% of stocks for revenue growth over the past 5 years. We weight them by market cap.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
195
Growth Stocks
High risk
$5.2K
Growth Stocks focuses on companies with strong growth prospects, often found in sectors driving innovation and technological advancement. This ETF invests in companies demonstrating robust revenue and earnings growth, including technology giants, healthcare innovators, and consumer discretionary leaders.
Top Sector
Information Technology
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
178
Value Stocks
Medium risk
$6.8K
This Strategy targets undervalued stocks in the U.S. market, emphasizing companies with solid fundamentals and potential for long-term growth. Emphasizing sectors such as healthcare, financials, industrials, and consumer goods, it seeks opportunities where market prices may not fully reflect underlying value metrics like earnings and book value.
Top Sector
Financials
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
337
USA Mid-Cap Companies
Medium risk
$3.8K
Targeting mid-sized U.S. companies, striking a balance between growth potential and stability. Investing in sectors like industrials, technology, consumer goods, and healthcare, it offers exposure to companies with established market positions and growth opportunities.
Top Sector
Industrials
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
316
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
Equal Weighted US Top 500
Medium risk
$3.1K
This index provides equal-weight exposure to the top 500 companies in the US, offering a unique approach compared to traditional market-cap weighted indexes. With an aim to reduce concentration risk by allocating equal amounts to each constituent, it potentially benefits from smaller companies' outperformance.
Top Sector
Industrials
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
502
US 1000
Medium risk
$33.0K
This strategy tracks a market-cap-weighted index of the 1000-largest US companies. It offers broad exposure to the US equity market, encompassing a diverse range of sectors and industries. By investing in this fund, you gain access to the performance of large and well-established companies within the US economy.
Top Sector
Information Technology
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
1000
Stock's related to MRNA
The stocks that are correlated to MRNA - Moderna, Inc. are BNTX, RCKT, CVAC, ADI, COHU
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
B BNTXBioNTech SE | 52.42% | $22.08B | +2.30% | 0.00% |
| 50.51% | $592.86M | -77.74% | 0.00% | |
C CVACCureVac NV | 42.83% | $637.03M | -4.05% | 0.00% |
| 42.34% | $89.71B | -5.77% | 2.18% | |
C COHUCohu, Inc. | 42.32% | $640.86M | -56.61% | 0.00% |
| 42.20% | $3.16B | -13.91% | 0.50% | |
D DIODDiodes, Inc. | 41.97% | $1.72B | -45.77% | 0.00% |
| 40.54% | $43.59B | -28.13% | 2.49% | |
| 40.48% | $2.80B | -49.80% | 0.00% | |
| 40.16% | $14.99B | -48.54% | 0.00% | |
Q QCOMQUALCOMM, Inc. | 39.82% | $154.20B | -17.87% | 2.53% |
| 39.28% | $1.93B | -44.90% | 0.00% | |
I IPGPIPG Photonics Corp. | 39.11% | $2.34B | -36.86% | 0.00% |
| 38.98% | $2.55B | -34.11% | 1.88% | |
| 38.93% | $713.23M | -72.41% | 0.00% | |
| 38.82% | $38.78B | -10.04% | 2.09% | |
C CGNXCognex Corp. | 38.68% | $4.57B | -32.69% | 1.20% |
F FORMFormFactor, Inc. | 38.63% | $1.96B | -44.42% | 0.00% |
| 37.82% | $5.93B | -41.82% | 0.00% | |
| 37.65% | $1.18B | -15.60% | 0.00% | |
ETF's related to MRNA
The ETFs that are correlated to MRNA - Moderna, Inc. are GNOM, IBB, BBH, XBI, ARKG
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 51.61% | $48.48M | 0.5% | |
| 47.55% | $5.70B | 0.45% | |
| 46.15% | $362.92M | 0.35% | |
X XBISPDR Biotech ETF | 44.71% | $5.06B | 0.35% |
| 43.23% | $987.53M | 0.75% | |
| 42.94% | $215.17M | 0.65% | |
| 42.64% | $3.00B | 0.46% | |
| 42.63% | $398.81M | 0.59% | |
| 42.52% | $67.12M | 0.75% | |
| 41.36% | $296.15M | 0.68% | |
| 40.85% | $208.53M | 0.68% | |
| 40.81% | $1.05B | 0.35% | |
| 40.52% | $932.95M | 0.95% | |
| 39.98% | $426.00M | 0.65% | |
| 39.84% | $600.30M | 0.15% | |
| 39.82% | $188.92M | 0% | |
| 39.76% | $40.15B | 0.04% | |
| 39.65% | $4.15B | 0.1% | |
| 39.55% | $40.10B | 0.07% | |
| 39.44% | $294.73M | 0% | |
News
Yahoo
Moderna stock and other vaccine makers are under pressure after Peter Marks resigned from the FDA. Is MRNA stock a sell?
Yahoo
The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.
Yahoo
The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has passed with no clarity on when the decision will move forward again.
Yahoo
In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). If Pfizer and Moderna can bounce back, purchasing their shares now might be a great move -- but which is the more attractive option? Pfizer has made important moves in the past few years that could pay off down the line.
Yahoo
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).
Yahoo
Moderna (NASDAQ: MRNA) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later stages of the coronavirus pandemic. Now, the biotech is trying to show the world that it can expand beyond coronavirus prevention as it has a full pipeline of programs ranging from latent viruses and rare diseases to cancer. In fact, its cancer vaccine is in late-stage development and has generated positive clinical data.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds